Jasper Therapeutics Highlights Briquilimab Data at AAAAI 2025
Jasper Therapeutics, Inc. is sharing promising new clinical data from its Phase 1b/2a BEACON study regarding briquilimab, an innovative antibody therapy focused on c-Kit to treat chronic mast cell-driven diseases. This presentation occurred at the AAAAI 2025 Annual Meeting in San Diego. The data, drawn from a January 31, 2025, cut-off, reveals that briquilimab maintains a strong safety profile with no new adverse events tied to c-Kit blockade. In light of these results, Jasper Therapeutics plans to kick off a Phase 2b study later in 2025, potentially positioning briquilimab as a fast and effective option for moderate to severe chronic spontaneous urticaria (CSU) patients. More data from studies with higher doses and larger patient groups will be available by mid-2025.
Key Highlights of the Findings
- Jasper Therapeutics is actively engaging with the medical community by presenting updated findings on briquilimab at the AAAAI 2025 Annual Meeting.
- The BEACON study results continue to reflect a well-tolerated drug with a favorable safety profile, bolstering confidence in briquilimab.
- A potential Phase 2b study is set to begin in the latter half of 2025, indicating progress toward possible market entry.
- Clinical expert feedback has praised briquilimab for its rapid and significant clinical responses in patients suffering from severe CSU, marking it as a unique treatment option.
Concerns and Considerations
- Numerous forward-looking statements in the press release denote potential risks and uncertainties that might foster doubt among investors regarding the drug’s future success.
- The anticipated mid-2025 data release could prolong the wait for stakeholders needing critical updates on briquilimab’s efficacy and safety, possibly dampening investor confidence.
- Despite a strong safety profile, the need for further data on dose selection raises questions about earlier trial results’ reliability, potentially affecting market outlook.
Frequently Asked Questions
What is briquilimab?
Briquilimab is a cutting-edge antibody therapy developed by Jasper Therapeutics that targets c-Kit for treating mast cell-driven diseases.
What key results were shared at the AAAAI 2025 Annual Meeting?
Data from the BEACON study highlighted briquilimab’s safety and efficacy for patients with chronic spontaneous urticaria.
When will the Phase 2b study for briquilimab begin?
The Phase 2b adaptive study for briquilimab is slated to begin in the second half of 2025.
How has briquilimab performed in clinical trials?
Clinical trials show that briquilimab has a favorable safety profile and demonstrates effective responses in patients with chronic spontaneous urticaria and related conditions.
What additional data is anticipated for briquilimab in 2025?
Further clinical data regarding patients treated with briquilimab at doses of 180 mg and higher is expected to be reported mid-2025.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$JSPR Insider Trading Activity
Insiders at $JSPR have conducted 2 trades in the last 6 months—none being purchases and both being sales.
Here’s a breakdown of insider trading activities related to $JSPR over the past 6 months:
- JEETINDER SINGH MAHAL (Chief Operating Officer) sold 1,800 shares, totaling an estimated $39,002.
To follow insider transactions, visit Quiver Quantitative’s insider trading dashboard.
$JSPR Hedge Fund Activity
In the most recent quarter, 45 institutional investors added shares of $JSPR, while 38 reduced their positions.
Here’s a summary of notable recent moves:
- AVIDITY PARTNERS MANAGEMENT LP decreased their holdings by 782,000 shares (-100.0%) in Q3 2024, impacting their portfolio by an estimated $14,709,419.
- POLAR CAPITAL HOLDINGS PLC also removed 581,538 shares (-100.0%) in Q4 2024, resulting in about $12,433,282 less in their holdings.
- Conversely, FMR LLC added 350,162 shares (+912.8%) in Q4 2024, increasing their portfolio by approximately $7,486,463.
- INTEGRAL HEALTH ASSET MANAGEMENT, LLC boosted their portfolio by adding 300,000 shares (+85.7%), which equals an estimated $6,414,000.
- OCTAGON CAPITAL ADVISORS LP cut down by 287,500 shares (-100.0%) in Q3 2024, affecting their holdings by about $5,407,875.
- CITADEL ADVISORS LLC increased positions by adding 282,046 shares (+199.2%) in Q4 2024, which equates to an estimated $6,030,143.
- ALLY BRIDGE GROUP (NY) LLC trimmed their holdings by 277,042 shares (-69.4%) in Q4 2024, for a decrease estimated at $5,923,157.
To monitor hedge fund portfolios, check out Quiver Quantitative’s institutional holdings dashboard.
Full Release
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology firm focused on developing briquilimab, a novel antibody therapy aimed at c-Kit for treating mast cell-driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. The company is presenting updated clinical data from the Phase 1b/2a BEACON study, along with findings from four preclinical studies on briquilimab, at the AAAAI 2025 Annual Meeting, occurring February 28 – March 3, 2025, in San Diego, CA.
The BEACON study update, reflecting data collected as of January 31, 2025, includes about one month of additional dosing and follow-up of the 49 participants from Jasper’s preliminary data disclosed on January 8, 2025. Briquilimab continues to showcase a well-tolerated profile, maintaining a favorable safety status with no further adverse events related to c-Kit blockade reported. The findings support advancing briquilimab into a registrational program for CSU, with a Phase 2b operationally adaptive study anticipated to begin in the second half of 2025. The final dose selection for this Phase 2b study will be informed further by additional clinical data involving patients treated at doses of 180mg and higher.
# Jasper’s BEACON Study Shows Promising Results for Briquilimab in CSU
“I am pleased to present updated data from the BEACON study at AAAAI, which continue to demonstrate that treatment with briquilimab leads to rapid and deep clinical responses in omalizumab-experienced patients with moderate to severe chronic spontaneous urticaria (CSU),” stated Thomas B. Casale, M.D., a Professor of Medicine and Pediatrics at the University of South Florida Morsani College of Medicine. “The safety profile observed is also highly encouraging, characterized by a low frequency of c-Kit related adverse events. These were transient, low-grade, and did not result in any dose delays or discontinuations. The favorable safety data reported in the study align with the predictable drug clearance observed, which may enable the restoration of signaling on c-Kit-expressing cells between doses. Furthermore, the early time to maximum (T
max
) observed was consistent with a rapid onset of clinical response. Taken together, I believe this data highlights the potential of briquilimab as a differentiated treatment option for patients with CSU.”
“We remain very excited by the efficacy and safety data generated in the BEACON study,” said Ronald Martell, President and Chief Executive Officer of Jasper. “We believe that these data illustrate briquilimab’s potential to stand out among other therapies, both approved and in development, particularly in terms of onset of action, depth of response, and safety/tolerability. With a significant number of additional patients enrolling in both the BEACON and SPOTLIGHT studies, alongside patients transitioning to the Open-Label Extension study, we anticipate reporting data from about 70 additional patients treated with briquilimab doses of 180mg or more around mid-year 2025. This data will guide our final dose selection for the planned Phase 2b operationally adaptive study expected to begin later this year.”
Presentation Details:
Abstract Title:
Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)
Publication Number:
L24
Session Title:
Late Breaking Oral Abstract Session
Session Type:
Oral Abstract Session
Presentation Date / Time:
Saturday, March 1, 2025; 2:55 p.m. PST
Abstract Title:
Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)
Poster Number:
L24
Session Title:
Late Breaking Poster Session I
Session Type:
Poster Session
Session Date / Time:
Saturday, March 1, 2025; 9:45 – 10:45 a.m. PST
Abstract Title:
Briquilimab, an Anti-c-Kit Antibody, Induces Durable Depletion of Mast Cells (MCs) Across Multiple Tissues in Mice Expressing Chimeric Human/Mouse CD117 (c-Kit)
Poster Number:
540
Session Title:
Novel Mechanisms of Mast Cells, Basophils and IgE
Session Type:
Poster Session
Session Date / Time:
Saturday, March 1, 2025; 9:45 – 10:45 a.m. PST
Abstract Title:
Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell Apoptosis
Poster Number:
541
Session Title:
Novel Mechanisms of Mast Cells, Basophils and IgE
Session Type:
Poster Session
Session Date / Time:
Saturday, March 1, 2025; 9:45 – 10:45 a.m. PST
Abstract Title:
Briquilimab, an Anti-Human CD117 Antibody, Prevents Epicutaneous Oxazolone-Induced Features of Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117
Poster Number:
662
Session Title:
Atopic Dermatitis, Contact Dermatitis, Urticaria, Angioedema
Session Type:
Poster Session
Session Date / Time:
Sunday, March 2, 2025; 9:45 – 10:45 a.m. PST
Abstract Title:
Briquilimab, an Anti-Human CD117 Antibody, Treats Low-Calcemic Vitamin D3 Analog MC903-Induced Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117
Poster Number:
690
Session Title:
Atopic Dermatitis, Contact Dermatitis, Urticaria, Angioedema
Session Type:
Poster Session
Session Date / Time:
Sunday, March 2, 2025; 9:45 – 10:45 a.m. PST
About Jasper
Jasper is a clinical-stage biotechnology company focused on the development of briquilimab for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell surface receptor c-Kit, which hinders signaling through this receptor. This mechanism disrupts a critical survival signal, leading to apoptosis in mast cells and reducing the inflammation in mast cell-driven diseases such as CSU and asthma. Jasper is actively conducting clinical trials of briquilimab involving patients with CSU, CIndU, and asthma. The treatment has already shown an effective safety profile and positive clinical results in both CSU and CIndU. For more information, please visit us at
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These statements may include words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that indicate future events
Jasper Therapeutics Addresses Forward-Looking Statements and Risks
Jasper Therapeutics has released a statement outlining various forward-looking statements that provide insight into the company’s expectations. However, these statements should not be seen as guarantees or definitive predictions of actual performance. Investors should be aware that these future prospects are illustrative and not meant for reliance as secure assurance.
The company emphasizes that many external factors could influence actual outcomes, including issues outside Jasper’s control. Notably, these forward-looking statements carry inherent risks and uncertainties, especially related to economic, political, and business conditions globally.
Understanding the Risks
Several significant risks could impact Jasper’s development process. For example, potential product candidates may not advance through clinical trials or gain necessary regulatory approvals within anticipated timelines, or at all. Clinical trial results could fail to match previously indicated safety or efficacy benchmarks. Additionally, Jasper is uncertain if it can successfully market its products or earn widespread acceptance among healthcare providers.
Patients’ willingness to pursue new treatments and physicians’ readiness to prescribe them also plays a role in Jasper’s future. Market competition poses another challenge, alongside the reliance on third parties for essential services like laboratory work, clinical development, and manufacturing. Moreover, external health crises can adversely affect business operations and supply chains.
Intellectual Property and SEC Filings
Moreover, maintaining adequate intellectual property protection for investigational products is crucial. There is also the risk of infringing upon the intellectual property rights of others. Investors are encouraged to review Jasper’s filings with the SEC, which detail these risks. Significant documents include the Annual Report on Form 10-K for the fiscal year ending December 31, 2023, and subsequent Quarterly Reports on Form 10-Q.
If any of these risks materialize or Jasper’s assumptions prove faulty, the actual results may diverge significantly from the forecasts presented in these forward-looking statements. Though Jasper might choose to update its forward-looking statements in the future, the company disclaims any obligation to do so. Therefore, investors should avoid relying on these statements as reflections of Jasper’s assessments beyond the date of this press release.
Contact Information
For investors:
Alex Gray
Jasper Therapeutics
650-549-1454
[email protected]
For investors:
Joyce Allaire
LifeSci Advisors
617-435-6602
[email protected]
For media inquiries:
Lauren Walker
Real Chemistry
646-564-2156
[email protected]
This article was originally published by Quiver News; read the complete story for more context.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
